ArticleCureus2026
Ertapenem-Associated Neurotoxicity in a Patient With Chronic Kidney Disease and Hypothyroidism: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenems are broad-spectrum antibiotics used to treat infections caused by multidrug-resistant organisms and are associated with neurotoxicity, especially in high-risk groups. Although ertapenem generally has a lower risk of seizures, factors such as advanced age, pre-existing neurological conditions, renal impairment, and hypoalbuminemia can raise the likelihood of adverse effects. We report a 92-year-old female with multiple comorbidities, including hypothyroidism, dementia, well-controlled post-stroke epilepsy, and chronic kidney disease, who developed a focal impaired awareness seizure on day 3 of IV ertapenem treatment for a multidrug-resistant urinary tract infection, despite prior tolerance to intravenous ertapenem, with complete resolution after discontinuation of IV ertapenem. This case highlights that ertapenem can be a potential precipitating factor for neurotoxicity in patients with a history of stable epilepsy and tolerance to the drug, particularly in those with advanced age and chronic kidney disease. Early recognition and discontinuation of the antibiotic are essential, as neurological symptoms are typically reversible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.